ADZENYS XR-ODT Drug Patent Profile

When do Adzenys Xr-odt patents expire, and when can generic versions of Adzenys Xr-odt launch?

Adzenys Xr-odt is a drug marketed by Neos Theraps and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has two patent family members in two countries.

The generic ingredient in ADZENYS XR-ODT is amphetamine. There are fifty-five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the amphetamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adzenys Xr-odt

A generic version of ADZENYS XR-ODT was approved as amphetamine by ACTAVIS LABS FL INC on June 22^nd, 2023.

Summary for ADZENYS XR-ODT

International Patents:	2
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	28
Clinical Trials:	2
Patent Applications:	4,326
Drug Prices:	Drug price information for ADZENYS XR-ODT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADZENYS XR-ODT
What excipients (inactive ingredients) are in ADZENYS XR-ODT?	ADZENYS XR-ODT excipients list
DailyMed Link:	ADZENYS XR-ODT at DailyMed

See drug prices for ADZENYS XR-ODT

Recent Clinical Trials for ADZENYS XR-ODT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Premier Research Group plc	PHASE4
Aytu BioPharma, Inc.	PHASE4
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2

See all ADZENYS XR-ODT clinical trials

Pharmacology for ADZENYS XR-ODT

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for ADZENYS XR-ODT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADZENYS XR-ODT	Extended-release Orally Disintegrating Tablets	amphetamine	3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg	204326	1	2016-05-10

US Patents and Regulatory Information for ADZENYS XR-ODT

ADZENYS XR-ODT is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-006	Jan 27, 2016	AB	RX	Yes	Yes			Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-006	Jan 27, 2016	AB	RX	Yes	Yes			Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-001	Jan 27, 2016	AB	RX	Yes	No			Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-004	Jan 27, 2016	AB	RX	Yes	No			Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-005	Jan 27, 2016	AB	RX	Yes	No			Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-002	Jan 27, 2016	AB	RX	Yes	No			Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-001	Jan 27, 2016	AB	RX	Yes	No			Y

International Patents for ADZENYS XR-ODT

See the table below for patents covering ADZENYS XR-ODT around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2726066	FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)
World Intellectual Property Organization (WIPO)	2013003622
World Intellectual Property Organization (WIPO)	2013003622
European Patent Office	2726066	FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)

Market Dynamics and Financial Trajectory for ADZENYS XR-ODT

Last updated: February 19, 2026

What is the current market position of ADZENYS XR-ODT?

ADZENYS XR-ODT (extended-release orally disintegrating tablet) is a formulation of amphetamine used primarily for Attention Deficit Hyperactivity Disorder (ADHD). It is marketed by Supernus Pharmaceuticals as an alternative to existing stimulant therapies. Launched in 2018, it competes with brands like Vyvanse, Concerta, and Adderall XR.

The drug's sales have seen steady growth, with revenues reaching approximately $165 million in 2022, up from about $80 million in 2018, reflecting increasing adoption.

How does ADZENYS XR-ODT compete within the stimulant market?

Key Competitors	Formulation	Market Share (2022)	Approximate Sales (2022)	Key Attributes
Vyvanse	Capsule	30%	$1.7 billion	Long-acting, low abuse potential
Concerta	Tablet	25%	$1.3 billion	Once-daily, methylphenidate-based
Adderall XR	Capsule	20%	$1.2 billion	Multiple strengths, high volume
ADZENYS XR-ODT	Orally disintegrating tablet	10%	$165 million	Fast onset, discreet use

The remaining market share is divided among other generics and newer formulations.

What are the key market drivers influencing ADZENYS XR-ODT's growth?

• Preference for disintegrating formulations: Patients with swallowing difficulties favor orally disintegrating tablets.
• Demand for long-acting stimulants: Ease of once-daily dosing enhances adherence.
• Prescribing trends: Growing awareness and diagnosis rates of ADHD increase prescriptions.
• Competitive pricing: As patent exclusivity wanes, generic competition influences pricing strategies.

What are the regulatory and reimbursement factors affecting ADZENYS XR-ODT?

ADZENYS XR-ODT received FDA approval in November 2017. It is available via insurance and Medicaid programs backed by formulary inclusion. While covered by major insurers, formulary position influences market penetration. Strategic negotiations and pricing influence uptake in managed care settings.

How are sales projected for ADZENYS XR-ODT over the next five years?

Year	Estimated Sales	Growth Rate (CAGR)	Notes
2023	$200 million	21%	Increased formulary coverage; brand recognition
2024	$245 million	20.5%	Expanded prescriber adoption
2025	$300 million	22%	Launch of new formulations and marketing
2026	$370 million	23.3%	Competitive pressure from generics
2027	$455 million	23.2%	Broader acceptance in pediatric use

Sources of growth include increased pediatric prescriptions, expanding geographic markets, and potential line extensions.

What are the primary risks impacting future sales?

• Patent expiration: Loss of market exclusivity could lead to generic entry, pressuring pricing.
• Competitive innovations: New formulations with improved profiles could erode market share.
• Regulatory changes: Stricter controls on stimulant prescriptions or scheduling could restrict access.
• Market saturation: Penetration reaches a ceiling as prescribing stabilizes.

What pricing strategies will influence the financial trajectory?

Supernus has employed value-based pricing, often above generics but below branded competitors, with discounts for insurance plans. Voluntary product discounts and rebates influence net sales figures.

What are the key indicators for investors monitoring ADZENYS XR-ODT?

• Market share trends
• Reimbursement policy developments
• Launch of new formulations or indications
• Regulatory and patent status
• Prescriber and patient adoption rates

Key Takeaways

ADZENYS XR-ODT maintains a niche in the stimulant ADHD market driven by patient preferences for disintegrating formulations and long-acting profiles. Sales growth depends on formulary coverage, competitive pressures, and patent protections. The upcoming years will see increased competition from generic versions and potential pipeline innovations affecting market dominance.

---

FAQs

1. When is ADZENYS XR-ODT expected to face generic competition?
Patent protection on the original formulation is expected to expire around 2027, opening the market to generic entrants.

2. How does ADZENYS XR-ODT compare price-wise to its competitors?
It is priced at a premium over generics but below branded counterparts such as Vyvanse, with average wholesale prices around $15–$20 per tablet.

3. What are the advantages of ADZENYS XR-ODT over other ADHD medications?
The orally disintegrating format allows for discreet administration and rapid onset, appealing to children and adults who prefer not to swallow pills.

4. Is there potential for new indications for ADZENYS XR-ODT?
Currently approved solely for ADHD, expansion into narcolepsy or other central nervous system disorders is unlikely within the near term.

5. How might healthcare policy impact ADZENYS XR-ODT sales?
Increased focus on cost-effective treatment and scrutiny of stimulant prescribing may influence adoption; favorable policies could enhance market access.

---

References

1. U.S. Food and Drug Administration (FDA). (2017). FDA approves ADZENYS XR-ODT for ADHD.
2. IQVIA. (2022). National Prescription Audit: Stimulants Market Share and Sales.
3. Supernus Pharmaceuticals. (2023). Annual Report.
4. Evaluate Pharma. (2022). ADHD Therapeutics Market Outlook.
5. Centers for Medicare & Medicaid Services. (2023). Formularies and Reimbursement Policies.